SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Oxygenta Pharma - Quaterly Results

14 Aug 2024 Evaluate
The topline surged 83.87% to Rs. 126.21 millions for the June 2024 quarter as against Rs. 68.64 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2024 is Rs. -13.63 millions as compared to Net Loss of Rs. -45.58 millions of corresponding quarter ended June 2023 Operating profit Margin for the quarter ended June 2024 improved to -17.61% as compared to -36.35% of corresponding quarter ended June 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 126.21 68.64 83.87 126.21 68.64 83.87 396.42 309.88 27.93
Other Income 0.22 0.00 0.00 0.22 0.00 0.00 0.42 0.18 133.33
PBIDT -17.61 -36.35 -51.55 -17.61 -36.35 -51.55 -96.54 -70.99 35.99
Interest 4.07 2.94 38.44 4.07 2.94 38.44 15.94 14.88 7.12
PBDT -21.68 -40.58 -46.57 -21.68 -40.58 -46.57 -112.11 -93.21 20.28
Depreciation 6.49 5.00 29.80 6.49 5.00 29.80 26.61 20.52 29.68
PBT -28.17 -45.58 -38.20 -28.17 -45.58 -38.20 -138.72 -113.73 21.97
TAX -14.54 0.00 0.00 -14.54 0.00 0.00 -103.92 1.98 -5348.48
Deferred Tax -14.54 0.00 0.00 -14.54 0.00 0.00 -103.92 1.98 -5348.48
PAT -13.63 -45.58 -70.10 -13.63 -45.58 -70.10 -34.80 -115.71 -69.92
Equity 354.84 334.84 5.97 354.84 334.84 5.97 334.84 142.01 135.79
PBIDTM(%) -13.95 -52.96 -73.65 -13.95 -52.96 -73.65 -24.35 -22.91 6.30

Oxygenta Pharma Share Price

57.66 1.60 (2.85%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×